CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...

CicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 Meeting KANSAS CITY, Mo., April 12, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the presentation of preclinical evidence...

CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a...

CicloMed Announces FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer KANSAS CITY, Mo., Oct. 11, 2017 (GLOBE NEWSWIRE) -- CicloMed LLC announced today that its development candidate for non-muscle-invasive and muscle-invasive bladder cancer, Ciclopirox Prodrug, was...